Use of Copeptin in Diabetes Insipidus
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Sep 11, 2013
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Purpose of this study is to compare the overall diagnostic accuracy of the three following diagnostic test procedures in diabetes insipidus (central, nephrogenic) and primary polydipsia: a) classical water deprivation test alone, b) classical water deprivation test plus plasma copeptin cut-off levels, c) hypertonic saline infusion test plus plasma copeptin measurement.
The investigators hypothesize that firstly b) and c) is better as a). Secondly the investigators hypothesize that c) is non-inferior to b).
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Polyuria or/and Polydipsia or/and therapy with synthetic adenovirus proteinase (AVP) derivate
- • Urine osmolality \<800mOsm/kgH20
- Exclusion Criteria:
- • Polyuria due to diabetes mellitus
- • Hypokalemia
- • Hyperkalemia (\>5mmol/l)
- • Hypercalcemia
- • Kidney disease (min.: glomerular filtration rate (GFR) 60ml/min/1.73m2)
- • Pregnancy
- • Hyponatremia \>135mmol/L
- • Hypernatremia \>145mmol/L
- • Hypo- or hypervolemia
- • uncorrected adrenal or thyroidal deficiency
- • Cardia failure
- • Epilepsia
- • Uncontrolled hypertension
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, Basel Stadt, Switzerland
Patients applied
Trial Officials
Mirjam Christ-Crain
Principal Investigator
University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials